文献速递新发突发、热带与寄生虫病

登革病毒1型活病毒人类挑战株的1期开放标签评估

A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain.
PubMed 文献 · J Infect Dis · 2021-01-01

这项1期开放标签研究纳入12名健康成人志愿者,使用登革病毒1型活病毒挑战株45AZ5,采用剂量递增设计评估安全性和表现。低剂量组6人接种0.5 mL 6.5×10³ PFU/mL,中剂量组6人接种0.5 mL 6.5×10⁴ PFU/mL。除低剂量组1人外均出现可检测病毒血症,平均潜伏期5.9天,平均病毒血症时间6.8天,未观察到严重不良事件或长期安全性信号,结论为该挑战株耐受良好,可能适用于治疗和预防产品的测试。

要点

  • 12名健康成人接种DENV-1-LVHC株45AZ5,低剂量组6人、中剂量组6人。
  • 除低剂量组1人外均出现可检测病毒血症,平均潜伏期5.9天。
  • 无严重不良事件或长期安全性信号,挑战株耐受良好。

核心结论

  • DENV-1-LVHC耐受良好,引起无并发症的登革热病,可能适合用于治疗和预防产品测试。

研究设计与样本

  • 1期开放标签研究,12名健康成人志愿者,使用登革病毒1型活病毒挑战株45AZ5,采用剂量递增设计。

主要发现

  • 低剂量组6人接种0.5 mL 6.5×10³ PFU/mL,中剂量组6人接种0.5 mL 6.5×10⁴ PFU/mL。
  • 除低剂量组1人外均出现可检测病毒血症。
  • 所有受试者平均潜伏期5.9天(范围5-9天),平均病毒血症时间6.8天(范围3-9天)。
  • 所有受试者平均峰值1.6×10⁷ GE/mL(范围4.6×10³至5×10⁷ GE/mL)。
  • 未观察到严重不良事件或长期安全性信号。

临床怎么用

  • 该挑战株可用于登革热治疗和预防产品的测试评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dengue human infection models (DHIM) have been used as a safe means to test the viability of prophylaxis and therapeutics. METHODS: A phase 1 study of 12 healthy adult volunteers using a challenge virus, DENV-1-LVHC strain 45AZ5, was performed. A dose escalating design was used to determine the safety and performance profile of the challenge virus. Subjects were evaluated extensively until 28 days and then out to 6 months. RESULTS: Twelve subjects received the challenge virus: 6 with 0.5 mL of 6.5 × 103 plaque-forming units (PFU)/mL (low-dose group) and 6 with 0.5 mL of 6.5 × 104 PFU/mL (mid-dose group). All except 1 in the low-dose group developed detectable viremia. For all subjects the mean incubation period was 5.9 days (range 5-9 days) and mean time of viremia was 6.8 days (range 3-9 days). Mean peak for all subjects was 1.6 × 107 genome equivalents (GE)/mL (range 4.6 × 103 to 5 × 107 GE/mL). There were no serious adverse events or long-term safety signals noted. CONCLUSIONS: We conclude that DENV-1-LVHC was well-tolerated, resulted in an uncomplicated dengue illness, and may be a suitable DHIM for therapeutic and prophylactic product testing. CLINICAL TRIALS REGISTRATION: NCT02372175.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Endy TP, Wang D, Polhemus ME, et al. A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain. J Infect Dis. 2021. PMID: 32572470. doi:10.1093/infdis/jiaa351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。